Improvement in visual function or an arrest in the decline of visual function as determined by an Ophthalmologist On review of a continuing authorisation period RANZCO have advised that the continued use of For stable patients on maintenance treatment, review intravenous immunoglobulin would be justified if function by an Ophthalmologist in collaboration with is the were to improve or if decline were to be halted. Long term treating specialist is required at least annually. use of intravenous immunoglobulin may be required in Clinical effectiveness of Ig therapy can be demonstrated cases where cessation of treatment is accompanied by by: disease progression. Improvement in visual function or an arrest in the decline of visual function as determined by an Ophthalmologist Induction Dose 1.5g/kg in divided dose over 3 days – Dose Recommended dose is Induction and maintenance doses have been defined 1.5 for three Maintenance Dose 0.4 to 1.5 g/kg in single or divided – months, with further doses monthly. maintenance dependent upon The aim should be to use the lowest dose possible that evidence of significant achieves the appropriate clinical outcome for each improvement in visual patient. acuity and ocular inflammation. Refer to the current product information sheet for Dosing 1 g/kg per further information on dose, administration and day is contraindicated contraindications. for some IVIg products. Refer to the current product information
Improvement in visual function or an arrest in the decline of visual function as determined by an Ophthalmologist On review of a continuing authorisation period For stable patients on maintenance treatment, review by an Ophthalmologist in collaboration with is the treating specialist is required at least annually. Clinical effectiveness of Ig therapy can be demonstrated by: Improvement in visual function or an arrest in the decline of visual function as determined by an Ophthalmologist RANZCO have advised that the continued use of intravenous immunoglobulin would be justified if function were to improve or if decline were to be halted. Long term use of intravenous immunoglobulin may be required in cases where cessation of treatment is accompanied by disease progression. Dose Recommended dose is 1.5 for three months, with further maintenance dependent upon evidence of significant improvement in visual acuity and ocular inflammation. Dosing 1 g/kg per day is contraindicated for some IVIg products. Refer to the current product information Induction Dose – 1.5g/kg in divided dose over 3 days Maintenance Dose – 0.4 to 1.5 g/kg in single or divided doses monthly. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. Refer to the current product information sheet for further information on dose, administration and contraindications. Induction and maintenance doses have been defined
Immunology-Ch7-Autoimmune-retinopathy-%28previously-Autoimmune-uveitis%29.DOCX